Fig 1.
Flow diagram illustrating study sample inclusion and exclusion criteria as well as the number of participants with and without AF during follow-up.
Table 1.
Baseline characteristics of participants by presence or absence of incident atrial fibrillation, multi-ethnic study of atherosclerosis (2000–2015).
Fig 2.
Kaplan-Meier survival estimates for the association between GlycA and atrial fibrillation.
Log-rank test: P = 0.64.
Fig 3.
Restricted cubic spline of the association between GlycA and atrial fibrillation adjusted for age, sex, race/ethnicity, MESA field site, education, health insurance, BMI, smoking status, pack-years of smoking, physical activity, systolic blood pressure, use of antihypertensive medication, total cholesterol, HDL-cholesterol, use of lipid-lowering medication, diabetes, eGFR, ln(CRP), ln(IL-6) and ln(fibrinogen).
The black curve represents hazard ratios for atrial fibrillation by proportion of population with the respective GlycA concentration. Grey boundaries represent the 95% CI of the hazard ratios. Knots were at the 5th, 35th, 66.5th, and 95th percentiles which correlates to GlycA levels of 289.8, 353.1, 400.2, and 488.8 μmol/L, respectively.
Table 2.
Incidence rates (95% CI) and hazard ratios (95% CI) for the association of GlycA with incident atrial fibrillation: The multi-ethnic study of atherosclerosis (2000–2015).
Table 3.
Incidence rates (95% CI) and hazard ratios (95% CI) for the association of CRP, IL-6 and fibrinogen with incident atrial fibrillation: The multi-ethnic study of atherosclerosis (2000–2015).